Repligen director receives RSUs and stock options

Repligen Corp director Karen A. Dawes received equity compensation consisting of restricted stock units and stock options.

Rhea-AI Filing Summary

Repligen Corp director Karen A. Dawes received equity compensation consisting of restricted stock units and stock options. She was granted 995 restricted stock units, each representing one share of common stock, which vest on the earlier of May 14, 2027 or the next annual shareholder meeting. She also received options for 2,239 shares of common stock at an exercise price of $103.38 per share, expiring on May 14, 2036. Following these awards, she directly holds 92,816 common shares. These are compensation grants, not open‑market purchases or sales.

Insider Trade Summary

Grant/Award: 3,234 shares

Grant/Award 2 txns

Insider DAWES KAREN A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	2,239	$0.00	$0.00
Grant/Award	Common Stock	995	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 2,239 contracts (Direct); Common Stock — 92,816 shares (Direct)

Footnotes (2)

1. F1. Ms. Dawes was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
2. F2. Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

Key Figures

Restricted stock units granted: 995 units Stock options granted: 2,239 options Option exercise price: $103.38 per share +3 more

6 metrics

Restricted stock units granted 995 units Equity award to director on May 14, 2026

Stock options granted 2,239 options Right to buy Repligen common stock

Option exercise price $103.38 per share Conversion or exercise price for stock options

Option expiration date May 14, 2036 Final expiration of granted options

Shares held after transaction 92,816 shares Total common shares directly owned after awards

Vesting date trigger Earlier of May 14, 2027 or next annual meeting Vesting condition for RSUs and options

Key Terms

restricted stock units, Stock Option (Right to Buy), contingent right, vest, +1 more

5 terms

restricted stock units financial

"Ms. Dawes was awarded 995 restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

contingent right financial

"Each restricted stock unit represents a contingent right to receive one share"

vest financial

"The restricted stock units vest on the earlier of May 14, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual meeting of the Company's shareholders financial

"or the date of the next annual meeting of the Company's shareholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Repligen (RGEN) director Karen Dawes receive in this Form 4 filing?

Director Karen Dawes received equity compensation awards, not open-market trades. She was granted 995 restricted stock units and stock options for 2,239 shares, both tied to Repligen common stock, as part of her director compensation package.

How many Repligen (RGEN) restricted stock units were granted to Karen Dawes?

Karen Dawes was granted 995 restricted stock units. Each unit represents a contingent right to receive one share of Repligen common stock, subject to vesting conditions tied to time and the company’s next annual meeting of shareholders.

When do Karen Dawes’ Repligen (RGEN) restricted stock units and options vest?

Both the 995 restricted stock units and the 2,239 stock options vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of Repligen’s next annual meeting of shareholders, whichever occurs first, according to the filing footnotes.

What are the key terms of Karen Dawes’ Repligen (RGEN) stock options?

Karen Dawes received stock options for 2,239 shares of Repligen common stock with an exercise price of $103.38 per share. These options vest on a time-based schedule and expire on May 14, 2036, if not exercised before that date.

How many Repligen (RGEN) shares does Karen Dawes own after these awards?

After the reported equity awards, Karen Dawes directly holds 92,816 shares of Repligen common stock. This figure reflects her position following the grant of 995 restricted stock units and 2,239 stock options disclosed in the Form 4 filing.

Were there any Repligen (RGEN) share purchases or sales in this Form 4?

The Form 4 shows no open-market purchases or sales by Karen Dawes. It only reports compensation-related acquisitions: 995 restricted stock units and 2,239 stock options, both granted at no cash cost per share on the transaction date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DAWES KAREN A

(Last) (First) (Middle)

C/O REPLIGEN CORPORATION

41 SEYON ST., BLDG 1, STE 100

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REPLIGEN CORP [ RGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		A		995(1)	A	$0.00	92,816	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$103.38	05/14/2026		A		2,239		05/14/2027(2)	05/14/2036	Common Stock	2,239	$0.00	2,239	D

Explanation of Responses:

1. Ms. Dawes was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

2. Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

	/s/ Jennifer Carmichael (Attorney in Fact)	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)